Drugs /

yttrium y 90 basiliximab

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.

Clinical Trials

View Clinical Trials for yttrium y 90 basiliximab

Yttrium y 90 basiliximab has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating yttrium y 90 basiliximab, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for yttrium y 90 basiliximab clinical trials.

T-cell non-hodgkin lymphoma is the most common disease being investigated in yttrium y 90 basiliximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Yttrium Y 90 Basiliximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating yttrium y 90 basiliximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
90y basiliximab, 90y basiliximab, yttrium y 90-labeled basiliximab, yttrium y 90 basiliximab
Drug Target(s) [2]:
IL2
NCIT ID [1]:
C99167

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.